The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero
VectivBio Holding AG (VECT)

VectivBio is a holding company. Through its subsidiaries, Co. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of treatments for rare conditions. Co.'s product pipeline is focused on rare gastrointestinal, or GI, disorders. Co. develops Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as for SBS-IF in patients with colon-in-continuity anatomy.

Company Name:  VectivBio Holding AG
Website:  www.vectivbio.com
Sector:  Biotechnology
July 1, 2022    1:53 PM Eastern


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Email EnvelopeFree VECT Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

VectivBio Holding AG (VECT) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2022, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.